2020 American Transplant Congress
B Cell Depletion with Anti-CD20 mAb Exacerbates Anti-Donor CD4+ T Cell Responses in Highly Sensitized Transplant Model
Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
*Purpose: Preformed donor-specific anti-human leukocyte antigen antibodies (DSAs) have been associated with detrimental effects in transplant recipients. To eliminate preformed DSAs, we desensitized DSA-positive recipients…2020 American Transplant Congress
T and B Lymphocyte Dynamics after Genetically-Modified Pig-To-Baboon Kidney Xenotransplantation with an Anti-CD40mAb-Based Immunosuppressive Regimen
1Surgery, University of Alabama at birmingham, Birmingham, AL, 2Revivicor, Blacksburg, VA, VA
*Purpose: We have evaluated recovery of T and B lymphocytes and their subsets after depletion by anti-thymocyte globulin (ATG) and an anti-CD20mAb (Rituximab), followed by…2020 American Transplant Congress
Rapid Preparation to Undergo ABO-Incompatible Living Donor Liver Transplantation for Acute Liver Failure
1Chang-gung Hospital, Taoyuan, Taiwan, 2Chang-gung Hospital, Taiyuan, Taiwan
*Purpose: Acute liver failure is a life-threatening condition and urgent liver transplantation is needed to save lives. In the circumstance of deceased and ABO-compatible (ABO-C)…2020 American Transplant Congress
Association between Response to Rituximab and Risk of Antibody-Mediated Rejection in ABO-Incompatible Living Kidney Transplantation
*Purpose: Owing to limited organ availability, ABO-incompatible living kidney transplantation (ABO-ILKT) has been used extensively. Various forms of preconditioning therapies have been used alone or…2020 American Transplant Congress
Impact of Rituximab and Apheresis Techniques in Acute Rejection Rates in ABO Incompatible Living Donor Kidney Transplant
*Purpose: ABO incompatibility (ABOi) is a widespread option of living kidney donor transplantation (LKDT). However, controversies in rejection, and death-censored graft survival rates are published,…2019 American Transplant Congress
Efficacy Of Rituximab Monotherapy On Anti-human Leukocyte Antigen Antibodies In Highly Sensitized Living Donor Kidney Transplant Patients.
*Purpose: We aim to examine the efficacy of Rituximab (RTX) monotherapy in reducing DSA in Highly Sensitised Living Donor Kidney Transplant (HS-LDKT) candidates and potentially…2019 American Transplant Congress
Variable Outcomes of Recurrent Autoimmune Diabetes Post Pancreas Transplant Treated with Rituximab
Washington University, St. Louis, MO
*Purpose: Demonstrate the outcomes of treatment with rituximab in patients with autoimmune diabetes after pancreas transplant.*Methods: We present the treatment response to rituximab in 3…2018 American Transplant Congress
The Impact of Rituximab Dose on Hepatitis B Virus Reactivation in HBsAg-Negative/anti-HBc-Positive Kidney Transplant Recipients
Background: Hepatitis B virus (HBV) reactivation is well-recognized complication of rituximab. Although use of rituximab for sensitized patients continues to increase in kidney transplantation, the…2018 American Transplant Congress
The Incidence of Polyomavirus-BK and Cytomegalovirus Infections in Renal Transplant Recipients Following Rituximab Administration
Northwestern Memorial Hospital, Chicago, IL.
Rituximab is an antibody that binds to the CD20 antigen on B cells resulting in rapid and prolonged depletion. At Northwestern Memorial Hospital, a single…2018 American Transplant Congress
Evaluation of FlowDSA Crossmatch for Detection of Donor-Specific HLA Antibodies
Background: Donor-specific HLA antibodies (DSA) are detected by different crossmatch techniques. Flow cytometric crossmatching (FCXM) is sensitive method, but it is subject to false (+)…
American Transplant Congress abstracts